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OBJECTIVES The study assessed clinical outcomes of closure device use following percutaneous coronary
revascularization using current standards of anticoagulation and antiplatelet therapy.
BACKGROUND Evaluation of the outcomes of patients by use of vascular closure devices during coronary
interventions employing current standards of anticoagulation and glycoprotein (GP) IIb/IIIa
inhibitor therapy is limited.
METHODS We evaluated outcomes of 4,525 consecutive patients who underwent percutaneous coronary
intervention between July 1997 and April 2000. All patients received anticoagulation with
heparin and GP IIb/IIIa inhibitor therapy with abciximab. The closure method was manual
in 1,824 patients, Angioseal in 524 patients and Perclose in 2,177 patients. Procedural and
hospital vascular outcomes were evaluated.
RESULTS Closure device success was 97.1% Angioseal and 94.1% Perclose (p  0.05). Minor vascular
complications occurred in 1.8% of manual patients, 1.1% of Angioseal patients and 1.2% of
Perclose patients (p  NS); major complications occurred in 1.3% of manual patients, 1.1%
of Angioseal patients and 1.0% of Perclose patients (p NS). Multivariate logistic regression
identified only closure device failure as an independent predictor of a vascular complication.
In patients with successful closure with a device, minor complications (0.8% vs. 1.8%, p 
0.05) and any complication (1.5% vs. 2.5%, p  0.05) were reduced compared to manual
compression.
CONCLUSIONS Arterial closure following coronary interventions using anticoagulation and GP IIb/IIIa
inhibitor therapy can be safely and effectively performed, with vascular complication rates
similar to or lower than with manual pressure. Additionally, vascular complication rates using
GP IIb/IIIa inhibitor therapy regardless of the method of arterial closure are equivalent to or
lower than previously published rates of vascular complications. (J Am Coll Cardiol 2002;
40:78–83) © 2002 by the American College of Cardiology Foundation
Femoral artery hemostasis can be achieved following sheath
removal after the completion of percutaneous coronary
interventions (PCI) using manual pressure or recently de-
veloped arterial closure devices (1–4). Two general types of
closure devices are available: suture-based devices (4–6) and
those that utilize a plug (7–9). Early studies examining the
safety and efficacy of these devices demonstrated effective-
ness in obtaining hemostasis in selected patients (4,8,10). A
recent report of a large clinical experience, however, indi-
cates that there is a higher rate of vascular complications
using closure devices (11) following coronary interventions.
Whether this is attributable to intrinsic limitations of the
closure devices themselves, or a result of a greater degree of
anticoagulation used during the coronary intervention, is
unknown. Use of potent antiplatelet therapy with reduced
anticoagulation is associated with lower bleeding complica-
tions than standard-dose heparin during PCI (12,13). Be-
cause only 6% of the patients in the previous study (11)
received glycoprotein (GP) IIb/IIIa inhibitor therapy, it is
possible that use of closure devices in patients treated with
combined antiplatelet and reduced anticoagulant therapy
may not be associated with increased vascular complications,
or that they may even be beneficial. As such potent platelet
inhibitor has become the standard of care in patients
undergoing PCI, it is important that the relative efficacy and
safety of manual and closure device hemostasis be deter-
mined in patients undergoing PCI receiving GP IIb/IIIa
inhibitors.
METHODS
Patients. Patients at our institution undergoing percutane-
ous revascularization using the femoral artery approach were
included in the study. Patients were not excluded based on
any clinical or procedural characteristics. A total of 3,643
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patients undergoing 4,525 PCI procedures using the fem-
oral approach between July 1997 and April 2000 form the
basis for this study. The study was approved by the
Institutional Review Board.
Percutaneous revascularization procedure. Patients un-
derwent percutaneous revascularization procedure using
standard techniques. Arterial sheath size ranged from 6 to
10F. Anticoagulation after sheath insertion was accom-
plished using intravenous (IV) unfractionated heparin to
achieve a target activated clotting time (ACT) of 200 to
250 s. Additional heparin was administered approximately
every 30 min to maintain the ACT in this range. Each
patient in the study received GP IIb/IIIa receptor inhibition
with abciximab according to usual protocol: 0.25 mg/kg
bolus followed by 0.125 mg/kg each hour IV infusion for
12 h. All patients were treated with aspirin 281 to 325 mg
a day. Patients receiving intracoronary stents received Ticlid
250 mg b.i.d., or Plavix 300 mg as a loading dose followed
by 75 mg/day.
Arterial closure. The method of arterial closure was cho-
sen by the interventionist. In patients in whom arterial
closure was contemplated, a femoral arteriogram was per-
formed via the arterial sheath. Patients generally did not
undergo arterial closure if: 1) the arteriotomy site was at or
below the femoral bifurcation; 2) the common femoral
artery was5 mm in diameter; and 3) extensive calcification
or plaque formation was present in the common femoral
artery. The type of arteriotomy closure was left to the
interventionist. Closure was performed using first-
generation closure devices including either a collagen-based
suture closure device (Angioseal, Daig, Minnetonka, Min-
nesota) or a suture-based closure device (ProStar, TecStar;
Perclose, Redwood City, California). Placement of either
closure device was performed according to standard tech-
nique. In the case of the Angioseal device a second bailout
or “buddy” wire was placed in the last 399 patients to ensure
vascular access in the event of device failure and was
removed after successful Angioseal deployment. The fem-
oral region around the arteriotomy site was infiltrated with
lidocaine with 1% epinephrine. Arterial closure was per-
formed in the cardiac catheterization laboratory using the
arterial closure device at the completion of the study. In
patients in whom arterial closure was not performed in the
laboratory, the sheath was pulled when the ACT was
180 s. Hemostasis out of the laboratory was achieved by
either manual pressure alone, or in conjunction with a
c-clamp. A pneumatic compression device, the Femostop
(USCI, Billerica, Massachussetts), was used when hemosta-
sis was not adequate despite manual pressure, or after an
arterial closure device was placed and hemostasis was not
adequately achieved. Ambulation was initiated in general
2 h after an arterial closure device was placed, and 6 to 8 h
following manual compression. A groin check was routinely
made postprocedure and prior to discharge, and recorded in
the chart.
OUTCOMES
Prior to hospital discharge the patient’s chart was evaluated
by a clinical research nurse. The hospital outcomes were
entered into an American College of Cardiology compatible
database (CAOS, IBS, Winston-Salem, North Carolina),
and these formed the basis for the outcomes in this study.
Procedural outcomes were reviewed at the completion of
each intervention procedure and entered into the database as
well.
Statistical analysis. Descriptive statistics (means and SD
of continuous factors, frequency counts and relative fre-
quencies of categorical factors) were computed by closure
type (manual, Perclose or Angioseal) and overall. Univariate
associations between treatment type and various complica-
tions or patient outcomes were examined using two-way
contingency tables and, where appropriate, associated odds
ratios (ORs) with 95% confidence intervals. These tables
were constructed using all available data (i.e., some patients
contributed more than one observation to the analysis).
Significance of associations between patient characteristics
and types of closure procedure were assessed using either the
Fisher exact test for two-way tables or, in the instances
when within-subject correlation was nonignorable (e.g.,
patient age, history of hypertension and other fixed prepro-
cedure characteristics), generalized estimating equations
(GEEs). To estimate associations between closure type and
complication outcomes in a setting that adjusted for possible
within-subject correlation, as well as important concomitant
risk factors, GEE multivariate logistic regression models
were employed. The GEE models use the technique of
Liang and Zeger (14) to control for within-subject correla-
tion while allowing for inclusion of both continuous and
categorical factors as covariates. All statistical analyses were
performed using SAS statistical analysis software (15).
RESULTS
Of the 4,525 patients in the study, 524 patients underwent
arterial closure with the Angioseal device, 2,177 patients
underwent closure with the Perclose device and the remain-
ing 1,824 patients underwent closure by manual pressure.
Table 1 displays the clinical characteristics of the patients in
each of the study groups. Not unexpectedly, there were
more patients with peripheral vascular disease in the manual
pressure group than in either of the arterial closure groups,
although this represented a minority of patients in the
manual pressure group itself (10%). The traditional risk
Abbreviations and Acronyms
ACT  activated clotting time
GEE  generalized estimating equation
GP  glycoprotein
IV  intravenous
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factors for coronary artery disease are also shown in Table 1,
and these were commonly present in patients receiving
closure devices. Diabetes was present in approximately 20%
to 25% of patients in all of the closure groups. The
procedural characteristics are shown in Table 2. Use of 10F
arterial sheaths was more commonly seen in the manual
pressure and Perclose groups (16% and 20%, respectively,
p  0.05 vs. Angioseal), whereas 9F sheaths were more
commonly observed in the Angioseal and Perclose groups
(37% and 44% vs. 22% manual, p  0.05). The type of
coronary intervention, number of vessels treated and proce-
dural success are also shown in Table 2. Number of vessels
treated and lesion characteristics were similar among the
three groups. However, atherectomy procedures were more
frequently performed in patients closed with the Perclose
and Angioseal devices.
The outcome of the arterial closure is shown in Table 3.
Failure to achieve adequate hemostasis or need for Femo-
stop closure device as part of the hemostasis process oc-
curred in 15 of the 524 Angioseal patients (2.9%), in 64 of
1,824 manual pressure patients (3.5%) and 128 of 2,177
(5.9%) Perclose patients (p  0.05 vs. Angioseal and
manual). Vascular complications associated with arterial
hemostasis are also shown in Table 3, while the OR and
95% confidence limits for outcomes are shown in Table 4.
Vascular repair was required in 15 of 1,824 (0.8%) manual
pressure patients, 1 of 530 (0.2%) Angioseal patients and 12
of 2,177 Perclose patients (0.6%) (p  NS). Significant
bleeding was defined as blood loss resulting in any of the
following: 3 g/dl drop in hemoglobin, blood transfusion,
prolonged hospital stay, hematoma 10 cm or retroperito-
neal hematoma. Significant bleeding was equally distributed
among all three groups and ranged from 1.1% to 1.7% (p 
NS among groups) Occlusion or loss of pulse occurred in 8
of 1,824 (0.4%) of manual-pressure patients, 1 of 524
(0.2%) Angioseal patients and 3 of 2,177 (0.1%) Perclose
patients (p  NS). Overall mortality was lower in the
Angioseal (0.2%) and Perclose (1.2%) groups than the
manual group (3.2%) (p  0.05). However, deaths directly
attributed to vascular complications occurred in two of the
Table 1. Patient Characteristics
Manual
(n  1,824)
Angioseal
(n  524)
Perclose
(n  2,177)
Age 64  12 62  12* 62  12*
Gender (M/F) 63%/37% 66%/34% 71%/29%*†
Hypertension 51% 62%* 61%*
Diabetes mellitus 20% 25%* 25%*
Smoking history 43% 55%* 52%*†
Hypercholesterolemia 41% 53%* 56%*
Vascular disease 10% 4%* 7%*
History of CABG 15% 9%* 16%†
Angina class IV 65% 78%* 78%*
Acute MI 14% 9%* 7%*
Cardiogenic shock 1% 0%* 0%*
*p  0.05 vs. manual. †p  0.05 vs. Angioseal.
CABG  coronary artery bypass grafting; MI  myocardial infarction.
Table 2. Procedural Characteristics
Manual
(n  1,824)
Angioseal
(n  524)
Perclose
(n  2,177)
Sheath size
6 1% 3% 1%
7 4% 5% 2%
8 57% 52%* 33%*†
9 22% 37%* 44%*†
10 16% 3%* 20%†
Number of vessels
1 81% 81% 76%
2 17% 18% 21%
3 2% 1% 3%
Lesion characteristics
A/B1 22% 19% 19%
B2/C 78% 81% 81%
Device
PTCA/Stent 74% 68%* 49%*†
Atherectomy 26% 32%* 51%*†
Procedural success 98.7% 99.6% 99.3%
*p  0.05 vs. manual. †p  0.05 vs. Angioseal.
PTCA  percutaneous transluminal coronary angioplasty.
Table 3. Closure-Device Outcomes (% Incidence)
Manual Angioseal Perclose
Closure success 96.5% 97.1% 93.9%†
Failure/Femostop 3.5% 2.9% 6.1%*†
Complications
Large hematoma (10 cm) 1.0% 0.4% 0.7%
Arteriovenous fistulae 0.3% 0.0% 0.1%
Pseudoaneurysm 0.5% 0.8% 0.4%
Loss of distal pulse 0.4% 0.0% 0.1%
Vessel occlusion 0.1% 0.2% 0.1%
Bleeding 1.1% 1.3% 1.7%
Retroperitoneal 0.5% 1.1% 0.4%
Other‡ 0.6% 0.2% 1.3%
Arterial dissection 0.1% 0.0% 0.0%
Vascular repair/surgery 0.8% 0.2% 0.6%
Death
Overall 3.2% 0.2%* 1.2%*
Vascular 0.3% 0.0% 0.1%
*p  0.05 vs. manual. †p  0.05 vs. Angioseal. ‡Significant bleeding other than
retroperitoneal bleeding as defined in the text.
Table 4. Closure-Device Outcomes: Closure Device
Versus Manual
Odds
Ratio
95% Confidence
Intervals
Minor complications
Angioseal 0.65 0.27–1.56
Perclose 0.68 0.40–1.14
Combined 0.67 0.41–1.10
Major complications
Angioseal 1.06 0.45–2.48
Perclose 0.76 0.42–1.38
Combined 0.82 0.47–1.43
Minor/major complications
Angioseal 0.83 0.43–1.61
Perclose 0.74 0.48–1.14
Combined 0.76 0.51–1.13
Minor complication hematoma10 cm; arteriovenous fistulae or pseudoaneurysm.
Major complication  vascular death/vascular repair/major bleeding/vessel occlusion
or loss of pulse.
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manual-pressure group, 0 of the Angioseal and 2 of the
Perclose group (p  NS). The outcomes of any closure
device use are shown in Table 5. Complication rates tended
to be lower with closure device use, but the differences were
not statistically significant.
Multivariate logistic regression (Table 6) was performed
using the clinical and procedural characteristics identified in
Tables 1 and 2. Only in laboratory closure device, failure
was identified as independently predictive of any minor or
major complication. Thus, although baseline differences
existed with respect to clinical and procedural characteristics
among the groups, they did not seem to have affected the
outcomes. We then re-examined the outcome data, exclud-
ing those patients who experienced failure of the closure
device in the catheter laboratory (Table 7). The incidence of
any minor complication excluding these closure-device fail-
ures was 1.8% manual and 0.8% combined closure device
(p  0.05); of any major complication 1.3% versus 0.9%
(p  NS); and of any minor or major complication 2.5%
versus 1.5% (p 0.05). Thus, successful closure appeared to
be associated with reduced overall events.
DISCUSSION
The major finding of this study is that arterial closure can be
performed safely and effectively with currently available
vascular closure devices in patients treated with anticoagu-
lation and potent antiplatelet GP IIb/IIIa inhibitor therapy
during coronary intervention procedures. Excluding those
patients with closure-device failure, our data suggest that
successful arterial closure may be associated with decreased
vascular complication rates compared to manual compres-
sion in patients receiving anticoagulant and GP IIb/IIIa
inhibition during PCI. Finally, vascular complication rates
of both the manual and closure-device groups are equivalent
to or lower than previously reported vascular complication
rates in patients undergoing coronary revascularization us-
ing heparin as the sole method of anticoagulation during the
procedure (4,11,16–18). These data suggest that use of the
arterial-closure devices, Angioseal and Perclose, should be
considered when early ambulation or continued anticoagu-
lation is indicated. Whether routine use of closure devices
will reduce the complication rate associated with sheath
removal remains to be determined.
Comparison to prior studies. Our findings differ from a
recently published large observational study suggesting that
closure devices are associated with increased vascular com-
plication rates following coronary interventions (11). There
may be several reasons for these apparent differences. First,
only 6% of their patients received GP IIb/IIIa inhibitor
therapy, with ACTs averaging 277 s (closure group) and
268 s (manual group). In our study ACTs were generally in
the 200 to 225 s range, substantially lower than in the study
of Dangas et al. (11). Thus, a greater degree of anticoagu-
lation may have contributed to the higher complication rates
Table 5. Closure-Device Outcomes
Manual
(n  1,824)
(% Incidence)
Combined Closure Device
(n  2,701)
(% Incidence)
Minor
Hematoma 10 cm 1.0 0.7
AV fistulae 0.3 0.1
Pseudoaneurysm 0.5 0.4
Major
Bleeding 1.1 1.6
Retroperitoneal 0.5 0.6
Other† 0.6 1.0
Vessel occlusion 0.1 0.1
Loss of distal pulse 0.4 0.1
Vascular surgery 0.8 0.5
Death
Overall 3.2 1.0*
Vascular 0.3 0.1
Any minor 1.8 1.2
Any major 1.3 1.0
Any minor and major 2.5 1.9
*p  0.05 vs. Manual. †Significant bleeding other than retroperitoneal bleeding as
defined in the text.
Table 6. Multivariate Logistic Regression Analysis
Multivariate logistic regression
Clinical variables
Age
gender
HTN
DM
Hyperchol
Hx of smoking
Vascular disease
Hx of CABG
Angina status
Hx of MI
Acute MI
Cardiogenic shock
Procedural variables
Closure type
Closure success
Sheath size
Number of vessels treated
Number of lesions treated
Lesion classification
Procedural success
PCI device
Regression outcome Significant variable
Any minor Sheath removal failure
Any major None
Any minor and major Sheath removal failure
CABG  coronary artery bypass grafting; DM  diabetes mellitus; HTN 
hypertension; Hx  history; Hyperchol  hypercholesterolemia; MI  myocardial
infarction; PCI  percutaneous coronary intervention.
Table 7. Closure-Device Outcomes Excluding Patients With
in-Laboratory Failed Angioseal and Perclose Devices
Manual
(n  1,824)
Combined Closure
Device
(n  2,553)
Any minor complication 1.8% 0.8%*
Any major complication 1.3% 0.9%
Any minor or major complication 2.5% 1.5%*
*p  0.05 vs. manual closure.
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seen in their study with closure-device use. Second, patients
chosen for arterial closure may have been different. Only
516 of 5,609 patients (9%) in the Dangas et al. (11) study
underwent arterial closure, whereas 2,701 of 4,525 patients
(60%) underwent closure in our study. Thus, higher com-
plication rates may occur in patients chosen because they are
perceived to be “higher risk” patients than if routine closure
is the practice, as was the case in our laboratory. Third, we
routinely performed femoral arteriograms prior to closure
device use, which may have prevented higher-risk patients
from receiving closure devices, and which may not have
been a practice in previous studies. Finally, the strategies of
“ad hoc” closure for higher-risk patients versus planned
closure for all patients (the standard at our institution) may
have had an effect on outcomes based on operator experi-
ence. The extent of training and experience in vascular
closure devices has been identified in a recent editorial as
one factor that may influence outcomes associated with
closure-device use (19). In our laboratory the closure-device
technique is considered part of the intervention procedure,
and thus both extensive training and experience were
provided for each operator using these devices. Whether
this significantly influenced the results remains to be deter-
mined.
Access site bleeding and GP IIb/IIIa inhibitor therapy.
Vascular complications associated with arterial access have
long been recognized to occur during cardiac catheterization
and percutaneous intervention procedures (6,16–18,20).
Factors associated with increased risk of complications have
been identified including the presence of vascular disease,
concomitant anticoagulation, older age, and at least in some
studies, multiple procedures (16–18,20). Studies have also
shown the level of anticoagulation with unfractionated
heparin had a substantial bearing on the bleeding rates (13);
with modification of the anticoagulation regimen, vascular
complications at the access site were significantly reduced.
An interesting observation from this study is that major
vascular complication rates were 0.9% for the combined
closure-device groups, and 1.3% for the manual-pressure
group, including a large number of patients with 10F
sheaths and complex coronary procedures. Major vascular
complication rates have been reported to range from 1.0%
(2) to over 3% (12) in intervention series, most of whom did
not receive GP IIb/IIIa inhibitor therapy. The reason for
this apparent low rate of major vascular complications is not
clear, but it does indicate that routine abciximab use itself is
not associated with vascular complications, as has been
recently suggested (21).
Limitations of closure devices. Although vascular devices
theoretically should minimize or eliminate complications
associated with hemostasis of the vascular access site,
existing data on closure-device outcomes in the aggregate
suggest that this may not be the case. Several reasons may
explain this, including incomplete closure, previous sticks or
multiple sticks at sites other than the closure site, and a
small but real incidence of spontaneous bleeding secondary
to the use of anticoagulant and antiplatelet therapy itself.
Our observation that successful arterial closure was associ-
ated with reduced vascular complication rates is intriguing,
and this suggests that development of more effective closure
devices should be pursued. Whether future generations of
arterial closure devices can substantially reduce or com-
pletely eliminate the complications associated with arterial
access site hemostasis remains to be determined.
Study limitations. Several limitations of the study merit
further discussion. This was not a randomized study; thus,
it may have inherent selection biases, which might have
influenced the results (19). The decision not to perform
arterial closure may have been made because of the presence
of vascular disease; thus, patients treated by manual pressure
may represent a higher-risk group of patients. However,
manual closure of the arterial access site in these patients
was done when the effect of anticoagulation was much lower
than in the closure-device patients, which might have offset
any potential increased risk introduced by the presence of
vascular disease. Second, vascular complications experienced
outside the hospital were not formally monitored. Anec-
dotal experience in recent published series indicate that late
infections may occur in approximately 0% to 3% of patients
undergoing closure with the Perclose device (2,5,6,10,21).
This study did not allow us to formally measure this
complication rate in our patient cohort. Although certain
biases may have been introduced, with respect to the
outcomes of the closure devices, the results reflect the use of
interventionists who felt most comfortable with the tech-
nique and, thus, likely the most optimal outcomes from
their use. Moreover, this experience represents “real world”
experience and, thus, is directly applicable to clinical prac-
tice.
Conclusions. In conclusion, arterial closure by Angioseal
or Perclose closure devices can be performed safely and
effectively following coronary interventions using anticoag-
ulation and GP IIb/IIIa inhibitor therapy, with vascular
complication rates similar to or lower than with manual
pressure. Moreover, vascular complication rates following
GP IIb/IIIa inhibitor use appear low regardless of the
method of closure.
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